Duncan McHale sold $2,262 of EVLO
Chief Medical Officer at Evelo Biosciences, Inc.. 6,854 shares at an average of $0.33, traded Nov 2, 2023, filed Nov 3, 2023.
Score components
- +15RoleOfficer
- 0Trade size$2k at market
- +10Share of holdings soldSold 34% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001694665-23-000168, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 1, 2023 | MOption exercise Common Stock10b5-1 | +12,500 | - | - | 20,441 | Nov 3, 2023 |
| Nov 2, 2023 | SOpen-market sale Common Stock10b5-1 | -6,854 | $0.33 | $2,262 | 13,587 | Nov 3, 2023 |
| Nov 1, 2023 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -12,500 | $0.00 | $0 | 25,000 | Nov 3, 2023 |
Related signals
Other insiders at Evelo Biosciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 5Weak | Evelo Biosciences, Inc. | Mark Bodmer CSO, President of R&D | $1,044 3,163 shares | -11% | |
| 2Weak | Evelo Biosciences, Inc. | Marella Thorell Chief Financial Officer | $598 1,811 shares | -8% | |
| 5Weak | Evelo Biosciences, Inc. | Simba Gill President & CEO | $57 172 shares | -1% | |
| 0Weak | Evelo Biosciences, Inc. | Duncan McHale Chief Medical Officer | $1,024 3,103 shares | -15% | |
| 5Weak | Evelo Biosciences, Inc. | Mark Bodmer CSO, President of R&D | $2,262 6,854 shares | -24% | |
| 7Weak | Evelo Biosciences, Inc. | Marella Thorell Chief Financial Officer | $1,320 3,999 shares | -19% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.